ScoreWhy is Arbutus Biopharma Corp. ?
1
With a growth in Net Sales of 98.68%, the company declared Outstanding results in Sep 25
- OPERATING CASH FLOW(Y) Highest at USD -44.7 MM
- NET SALES(HY) Higher at USD 11.27 MM
- NET PROFIT(HY) Higher at USD -4.43 MM
2
High Institutional Holdings at 65.39%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
3
Market Beating Performance
- The stock has generated a return of 34.76% in the last 1 year, much higher than market (S&P 500) returns of 16.12%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Arbutus Biopharma Corp. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Arbutus Biopharma Corp. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Arbutus Biopharma Corp.
27.14%
0.83
48.82%
S&P 500
13.68%
0.84
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
18.89%
EBIT Growth (5y)
7.30%
EBIT to Interest (avg)
-46.95
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.36
Sales to Capital Employed (avg)
0.12
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
65.39%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
10.83
EV to EBIT
-23.89
EV to EBITDA
-24.42
EV to Capital Employed
-61.97
EV to Sales
51.28
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-34.66%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend24What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -44.7 MM
NET SALES(HY)
Higher at USD 11.27 MM
NET PROFIT(HY)
Higher at USD -4.43 MM
ROCE(HY)
Highest at -45.88%
RAW MATERIAL COST(Y)
Fallen by -31.13% (YoY
-1What is not working for the Company
CASH AND EQV(HY)
Lowest at USD 191.79 MM
Here's what is working for Arbutus Biopharma Corp.
Net Sales
At USD 11.27 MM has Grown at 267.63%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -44.7 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Higher at USD 11.27 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Net Profit
Higher at USD -4.43 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Net Profit
At USD -4.43 MM has Grown at 87.47%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Raw Material Cost
Fallen by -31.13% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Arbutus Biopharma Corp.
Cash and Eqv
Lowest at USD 191.79 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
